Latest / Powering the Future Within / Episode 16: Giving Hope To Those That Feel Hopeless - ShiraTronics' Pioneering Approach to Migraine
Transcript
- speaker-0: Welcome to Powering the Future Within, the podcast where we explore the breakthroughs shaping the future of MedTech. I'm Omari Bauchknight, CEO of ResidentLake Medical. Each episode, we speak with a leader who is driving the next wave of medical innovation, advancing technologies that are smarter, less invasive, and more connected than ever before. This is where the future of health takes shape. Let's dive in. Today, I'm excited to welcome Rob Benny to the podcast. Rob is a seasoned MedTech executive and CEO with more than two decades of experience leading innovative healthcare companies from early development through commercialization, growth, and successful acquisition. He currently serves as CEO of Sheeratronics, a company developing a novel neuromodulation therapy for chronic migraine. Over the course of his career, Rob has held several leadership roles across a number of high-growth medical technology companies, helping bring new therapies to patients while creating significant value for investors, clinicians, and healthcare systems. Today, we'll explore the lessons he's learned building medtech companies, leading teams through clinical inflection points, and turning breakthrough technology into lasting clinical impact. Rob, welcome to Powering the Future Within. speaker-1: Thanks, Amari. I really appreciate the ⁓ the opportunity. And ⁓ not gonna lie, you're ⁓ setting a very high bar for ⁓ radio voiced. So Joe Rogan, watch out. Very impressed. Very impressed. speaker-0: Well, really, really excited to to have you on the show. You know, I've followed your your career for for quite some time, ⁓ back to back to Intersect ENT. And one of the aspects of your background that I find really interesting is that you've spent a good portion of your career really focusing on conditions that have generally been unaddressed or under addressed by by medical technologies. I'm curious, what got you into med tech to begin with and What draws you to these domains that require fairly significant medical education and and market development? What ⁓ real what really gets you going? speaker-1: Yeah. ⁓ well thank you for the question and and ⁓ I'll try to try to encapsulate my ⁓ my med tech ⁓ career and that passion for market development and and innovative therapies quickly. I think as you know, I was ⁓ a ten year veteran in the pharmaceutical space back in the nineties and After a series of acquisitions, you know, during that time, I ⁓ I had a couple of very good friends that had moved over to medical technology and specifically Boston Scientific. And I I remember speaking to them daily and it w they were talking about, you know, the the speed with which innovation was happening and ⁓ they were getting really excited about this this new drug eluding stent launch for coronary, you know, artery disease. And I I just was enamored, you know, with again the the level of satisfaction they had in their role and then also the speed with which it appeared that, you know, medical technology was addressing unmet needs. And in this case it it it pertained to, you know, the advent of of drug eluding stents. And ⁓ and so I actually an opportunity came up and I I made a a switch to ⁓ Boston Scientific and had a chance. to join ⁓ Sidemed at the time, the SidMed division, which ⁓ involved the launch of of taxis and also their peripheral line of of of of interventional products. And ⁓ and that began the, you know, the lifelong passion for me of, you know, being a part of high growth med tech companies. Now obviously, ⁓ you know, back then Boston was still, you know, in just a rocket chip of growth, right? It was not near the, you know, the market cap it is today. But ⁓ It was just a exciting time to watch a company go from being a bare metal stent company to all of a sudden introducing this, you know, landmark technology that you know was was just taking the the world by storm and and and advancing clinical care. and candidly I thought that I was going to retire at Boston Psy. ⁓ you know, Boston had a way of making you feel like you'd reached the apex and ⁓ and that was until I met ⁓ Fred Kashravi and Leslie Trig. And they convinced me that ⁓ taking a ⁓ a ride with them, right, into a a small private equity-backed, you know, ⁓ company at the at the time it was Access Closure, ⁓ and launching this new innovative platform that was spinning out of Fred's ⁓ incubator was the best thing for my career. And I remember distinctly ⁓ Leslie and Fred telling me that if I if I played my cards right, that would be the last time I had to update my resume. And ⁓ you know, life is ⁓ is is ⁓ you know always good by you know when you look back in the rear view and and but it was quite fortuitous ⁓ because as it were, it was the last time I've updated a resume. It was two thousand and six. So ⁓ you know, I had a chance to participate again in a ⁓ high growth private equity, you know, organization. ⁓ at Access Closure, we were introducing a novel therapy, you know, trying to flip the the you know, the kind of the stale static world of vascular ceiling on its head. And we we I had a chance to work with just some incredible talent incredibly talented individuals. ⁓ and I and I got a flavor for, you know, what a you know zero to seventy million dollars a year type business ⁓ you know, w was all about. And I had just a a a a MBA type of learning experience, you know, in that in that, you know, several years, five years that I was there. and and then it as you point out, from there the my career has has has really followed suit. It's been a rinse and repeat. ⁓ not in the same therapeutic areas, ⁓ and that's been by design. I've had a chance to ⁓ launch a novel, you know, drug eluding stent platform and at Intersect D T ⁓ and then followed by a a a novel you know device for postpartum hemorrhage at a lydia and now ⁓ I've got the opportunity we're on the precipice of of being able to launch a ⁓ a novel approach to treating ⁓ chronic migraine. ⁓ and you know again it's it's by design. I've I've I find ⁓ great satisfaction in learning new therapeutic areas. ⁓ but what you'll notice is the common denominator is that I ⁓ have have sought out ⁓ game changing, you know, opportunities, ⁓ ones that candidly require a heavy lift from a market development standpoint. ⁓ you know, it it requires a certain skill to be able to, you know, introduce novel technologies to a market and oftentimes in marketplaces that ⁓ have existing standards of care. And ⁓ and at the end of the day that's that's really where I've anchored my career and it's it's something that's, you know, been very fulfilling for me personally. speaker-0: Right. So if you go back to that that decision, you you're at Boston Scientific Sci Med and then Boston Scientific, as you mentioned, part of one of the most probably prolific launches in the history of medical technology, rolling out drug eluding stents, which I think is probably one of the fastest adopted technologies in history. A great company, you're looking at making your rest of your career there. What was it about that those conversations that made you willing to make the jump? into ⁓ into a private company. speaker-1: I I wish I had a dazzling answer for you here. But I but I really don't. You know, I earlier in my career, I ⁓ I I will say that, you know, some of my moves, in particular going from Boston Scientific to Access Closure, was a bit of happenstance. ⁓ the the one ⁓ key attribute is that I have ⁓ historically in my career followed people, people that I believe in. People that I find to be extremely intelligent. ⁓ they're at the top of their game, you know, great strategists and and innovators. ⁓ and in in ⁓ Frank Kashravi and Leslie Trig, I I found just that. And and they they told a compelling story and I followed. and and I will tell you that it was the best career decision that I ever made. ⁓ I I think my next moves were much more intentional. But back then ⁓ it was one of ⁓ really belief in in people and I believed very much in in what Fred and Leslie were doing. speaker-0: Well, you must have great instincts on people because those are two ⁓ super high quality legendary names in the space. speaker-1: I think I I think I do. I may not be the smartest guy in the world, but I do have some decent intuition when it comes to people. speaker-0: Yeah, and and great intuition around people with Intersect ENT. That's one of the stories that required significant market development and education. And you joined even pre FDA approval, I believe, and then helped lead the growth to over a hundred million dollars in sales over time. What what were some of the lessons? What did it take to go from zero to a hundred? speaker-1: ⁓ you know, I I would say all the descriptors of of what you would expect, you know, in a early stage startup applied here, right? I mean, adaptability, a growth mindset, being resilient, you know, not not being afraid to fail, you know, being relentlessly focused on execution, hiring exceptional talent, like all of those, you know, were were applicable in the Intersect D T story. You know, I will tell you that I did to your point join pre FDA approval. ⁓ and much like our last, you know, point that we made around people, I had the I was the benefactor of of being able to follow Lisa Earnhardt ⁓ to Intersect. And Lisa, as you know, is is is the best of the best. and being able to join, you know, just after our pivotal study was completed prior to FDA approval, I had I had ample time to spend with her and to ideate on what a good limited commercial launch might look like. And and I will tell you that you know, again, when you go into these commercial launches, you don't know what you don't know. So I think being really thoughtful about, you know, sort of every phase of the launch is critically important. And what I mean by that is ⁓ you know, earning the right to move to the next phase of of of growth and expansion. And that was the type of of of approach that we took with ⁓ with Intersect D T. And I'll contrast Access Closure to Intersect ENT. Access was a a tremendous growth story. ⁓ but our our our priorities ⁓ at times really were driven by top line growth and we drove a lot of it. ⁓ whereas when Lisa and I sat down, you know, some of the the sort of guiding principles that we aligned to was, you know, w ⁓ really articulating clearly what are the metrics that will define our success, right? Meaning ⁓ we wanted deep adoption and penetration in a handful of territories. and we prioritize what we would call quality revenue over quantity, right? And ⁓ you know, we were able to go into a handful, in this case it was six territories. And I broke that first phase into what I called the education phase, right? We had a license to learn, ⁓ we had a license to fail. And during that time we were taking our original, you know, playbook that we thought we, you know, thought was the right go to market strategy and we were refining because in in our case at Intersect in the first year, you know, there were a couple of of speed bumps, right? And and you have to you have to be adaptable, be able to, you know, look at problem and find new solutions. And those are the type of people we tried to hire for the the original commercial team. and you know at that point, again, we had a really crisply articulated set of metrics that were usually built around, again, defining that recipe for success around depth, adoption, penetration. ⁓ and we were, you know, learning along the way and then ultimately earning the right to the next phase of growth. So phase one was education. Phase two I called replication. ⁓ at that point, you know, we were really focused on on getting reps to cash flow break even, you know, and and and helping them to, you know, again, pay for themselves. And once we did, replication phase was earned and we went into made a conscious decision to go into. ⁓ what I would call tier two and tier three markets. So instead of going to the New Yorks, you know, the Atlantis, the Houstons, the Dallas, we actually opted to to go hire best best athletes in Tulsa, Oklahoma. We went into the upstate of New York, like Syracuse, Albany area, ⁓ to, you know, in the into San Francisco. And California's not always a a tier one market due to some of the, you know, the the health ecosystem there ⁓ and payer mix and whatnot. But we we went into those markets and what we were trying to do was replicate ⁓ the early success that we had in phase one, that education phase. And sure enough, ⁓ and during that phase, by the way, we also started to pilot new new roles, right? Maybe take a little cost out of the model, ⁓ looked at maybe some junior reps, market development specialists, per diemes, ⁓ to help all support growth and again that focus on driving depth and adoption. And at that point, right, having worked through the education, then the replication phase, ⁓ that was when the board kind of looked at me and was like, Well, what are you waiting for? Right. It's time to execute and you know, and and and I really think that that thoughtful approach was the right one toward toward building that that market. ⁓ because at that point when when we got the green light, like let's go execute, let's go out and and ⁓ and you know, ⁓ grow, you know, exponentially. At that point, ⁓ we kind of really had things tight, right? We had the playbook refined, the objection handling, this the targeting, the hiring profiles, all that was really well baked so that we could ⁓ you know, in essence, kind of put on a clinic when we had the resources to go out and scale and grow, you know, quickly. And we did that, you know, as a result of, you know, having a successful IPO. and ⁓ the rest was kind of history if you speaker-0: Yeah. I I can imagine in in the early years there was just a tremendous amount of learning. And it sounds as though you were you were pretty thoughtful about putting in place key performance indicators or at least learning what those were so you could really understand how you could replicate it. I love those different phases of of the launch. I I'm curious. So I mean we're talking about intersect ENT, so obviously we're talking about the ENT space and and you're focused on chronic sinusitis. My understanding is the operator, the one who would perform these procedures, it wasn't so typical for them to have medical technology reps as a call point. They weren't so used to being called on, if you will. I'm curious if you started to kind of uncover a profile of the type of physician who would be more interested in in adopting an innovative technology like this versus others. speaker-1: Yeah, ⁓ and and I guess just a point of clarification. So the ENT specialty ⁓ I would suggest you actually was accustomed to ⁓ having, you know, med device representation. ⁓ and that was our that was our primary call point, right? These are the ENT surgeons. ⁓ a Clarent had just gone before us and so they had done a nice job of building, you know, the balloon signoplasty market. ⁓ and they're they're historically, ⁓ to your point. you know, they they maybe didn't have as much exposure to med tech reps that were introducing novel, you know, innovative, you know, disposable technologies like we were. ⁓ I would say, you know, Clarent and TELUS and then us were were sort of a a new breed, if you will, 'cause a lot of times prior, you know, the surgical procedures were rigid instruments, right? I mean it was a, you know, surgical procedure or navigation. ⁓ so they did have, you know, some ⁓ exposure to, you know, the the med tech profile. And ⁓ so when I when when we came in, I don't think it was a a heavy lift. I mean I think at that point a Clarence had done a really nice job of I'd call it seeding the market right and and setting the expectation. We did walk into a little bit of a political struggle because again, you know, as a Claren introduced, you know, ⁓ a a novel new procedure and technology, it created some you know, fraction within the specialty, meaning, you know, the some of the key opinion leaders, you know, rhinology thought leaders weren't as ⁓ I think appreciative of the necessarily the, you know, introduction to, you know, the market of a new technology like that. and so we kind of walked into a little bit of the crossfire, but we were able to, I think, you know, act as a unifying force as a as an organization. speaker-0: Right. Okay. So you would say that this at that call point the physician was eager and interested in seeing new technology brought through? speaker-1: I think I you know, I think that there was some receptiveness, ⁓ for sure. I and again, I give ⁓ the Blue Insignioplasty teams a lot of credit for ⁓ really priming the market, if you will. And I think what we ended up doing was I think brought a you know, a a first of its kind, you know, PMA approved platform technology ⁓ with good science behind it. And that was i in in essence a little bit of a differentiator. ⁓ from say the you know the balloon sineoplasty companies and ⁓ we were really proud of that. We had, you know, level one A evidence and ⁓ and candidly, you know, I think the team did just a remarkable job of of again introducing, you know, a a a very disruptive and innovative platform like, you know, the Propel Stent. ⁓ you know, during a time when there was a lot of political kind of churn going on within the specialty. I think they did a great job with it. speaker-0: That's fantastic. So up to that point, you know, you kind of charter your path and and a lot of experience in vascular, neurovascular, cardiovascular, ⁓ moving into the ENT space is a little bit of a of a pivot, but at the same time still that kind of stent profile. But in 2020, you stepped into the role at Olydia Health, ⁓ which developed a the Jada device for postpartum hemorrhage. The company, the technology has been a fantastic success and had such a needed area. Curious on your perspectives on on what were some of the important success factors there. speaker-1: ⁓ yeah. I ⁓ you know, I I had a nine year run at at Intersect and it was again, much like the time at Access Closure was a fantastic learning experience for me. ⁓ yeah, I had had several CEO opportunities come across my desk and ⁓ I really had vowed that I wasn't gonna I I was so committed to our team and our our success and wanted to continue, you know, to to grow there. But at the same point in time I was I was getting the bug, right? trying new things and and the CEO role became you know, pretty ⁓ pretty appealing to me. ⁓ and Olydia just ⁓ you know, I connected with the story at Olydia. I'm I'm I very much am a mission driven person. ⁓ at the end of the day, it's what gets us up every day. And if you can have, you know, a mission like we had at Olydia, boy, you you get up Cants on fire every single day. I mean, you had we had the opportunity to ⁓ introduce a novel new treatment option ⁓ for the treatment of postpartum hemorrhage and abnormal uterine bleeding in a space that was largely run by ⁓ pharmacologics, right? ⁓ you know, typically when a bleed happens, ⁓ you know, physicians customarily would just use uterotonics. And y it's very difficult to identify who the responders are going to be. So When one didn't work, they use another, then they use another, right? And threw the kitchen sink at And we were using just a a novel platform ⁓ that used st simple wall suction that was in the the OR ⁓ in the delivery room. And ⁓ and we were ⁓ mimicking the effects mechanically of a uteronic. Essentially we were trying to ⁓ draw in the walls of the uterus, ⁓ which then triggered to to the to the body, right, that we need to stop stop. you know, pushing blood into the uterus, right? Baby's been delivered time out, right? And so ⁓ and it was a it was a when you look at it, it was a a a simple concept, ⁓ and an absolutely brilliant idea. And so I was I was connected to, you know, again, the innovative, you know, aspects of the platform and really driven by a mission of saving moms, preserving families that it just became a a no brainer for me. ⁓ you know, the board dynamic was great. ⁓ we were we we had an opportunity, you know, when I joined to raise a small round of fund fundraising. ⁓ and then, you know, was was able to ⁓ submit our, you know, our our ⁓ our five tank K submission and then oversee, you know, the approval. And then had the chance to do what I really love to do, which is, you know, hire the initial, you know, commercial team. And just so happens that a number of those individuals ⁓ were individuals that were some of the you know the founding team at Intersect. So we kinda rinsed and repeated. and I'm a big believer that you you don't necessarily need to have domain expertise ⁓ when you're launching these early startups, you need to have market builders. You need to have people that know how to introduce technologies. ⁓ you need to have people that know that know how to extract key learnings and and then refine playbooks. ⁓ and all those elements, you know, were were were in the DNA of the early, you know, Olydia team and and to your point, you know, I I look at the success now and and ⁓ I really do think that, you know, some of those early decisions we made around, you know, targeting, around, you know, market introduction, around messaging, all, you know, carried through ⁓ you know, f with regard to our, you know, longer term executions. So speaker-0: So one of your one of your first major milestones or targets was to to raise funding. How how what was your experience like with fundraising at that time and in that space? speaker-1: Yeah, it's it was a di it's a different scale. ⁓ you know, women's health, unfortunately, it just does not command the same level of of investment, same level of attention, despite the fact that, you know, women make up most of the healthcare decisions, ⁓ and obviously ⁓ comprise a big portion of the population. And fortunately it just you know, when when I contrast the fundraising experience at Olydia to the fundraising experience with a company like Sheeratronics it it's night night and day different. ⁓ but the good news is we had a a handful of investors that, you know, believed in the mission, they believed in, you know, our early commercial plans. They believed in the the technology and they they they they took the you know the risk ⁓ and and and lo and behold it ended up paying off for them. ⁓ you know, I will say ⁓ after we had, and this is pretty typical of any startup, after we had burned down a a a number of risks and gotten approval in hand, I was running a parallel path of a series D at that time. With all the risk that we had burned down, there there was a lot more interest. ⁓ and I do believe we were gonna be able to raise a much larger round ⁓ had we not transacted. But as it were, we ended up with three ⁓ offers and ⁓ ended up transacting to Oregon on. speaker-0: Well, and hopefully with with the great success at Olydia it has helped or is helping to unlock additional investment in in the space. ⁓ but it's certainly the case that as you drive commercialization you start to have some success, hopefully that also unlocks additional opportunity. speaker-1: Indeed. Yep. I I we're seeing s you know, I had hoped to see more deal flow ⁓ in women's health as a result of our exit because it was a really great return for investors. ⁓ and I just haven't seen the again the the transactions happen at the pace I would like to see. And I think it's ⁓ unfortunate because there's some really great assets out there with some real innovation. ⁓ but that said I I've seen a lot more activity, a lot more focus on women's health. And I believe it's coming. It's just been a little bit slower than I had hoped 'cause the the space deserves attention. speaker-0: Absolutely. Absolutely. ⁓ and so let's talk transition to cherotronics in another space that requires attention, which is chronic migraine. It's been classified by the World Health Organization as a top five disabling condition globally, yet it's still rarely talked about with the same emergency as some other chronic, serious conditions. Why do you think it's been so much underestimated or under treated? speaker-1: Yeah. it's a that's a really good question and I I I appreciate you ⁓ kicking off our discussion around serotonics, you know, with that question. You know, it's unfortunately it it has an it has a frustrating answer ⁓ for many as it, you know, in my estimation underscores the gap between disease burden and public perception. ⁓ I think it's important I guess to note that, you know, migraine is largely an invisible disease. ⁓ people with migraine candidly, they they look healthy and depending on the day, they can operate like any non-migra would. ⁓ they don't have casts, they don't they're not in wheelchairs, they don't have visible tremors ⁓ that identify you as as a as a migraineure. ⁓ and as a result, you know, those that suffer with it they often do so in silence and without recognition. ⁓ unfortunately, you know, most human beings, myself included, you know, empathetically you, you know, you connect with those with conditions you know, that you can see and ⁓ and that carry mortality with them. You know, patients taking, you know, cancer treatments on a weekly basis and are sick all the time, you know, I get it. you know, patient that had a stroke ⁓ and is rehabbing from partial paralysis, got that. You know, a patient with Parkinson's and living with ⁓ uncontrollable tremors, yep, you know, I I kinda get that one as well. But a patient that was just at work yesterday, you know, laughing with coworkers, but now can't seem to get out of bed, you know, for two, three days, and that that one's just a little bit of a head scratcher. ⁓ appears a little less severe to me, or just in terms of of perception. So I think that is a a a big, you know, barrier that we have to overcome as it pertains to, you know, ⁓ creating more sensitivity to those that suffer with migraine. ⁓ you know, the the reality is is that the word headache somewhat trivializes the disease and the suffering, as, you know, most remember a time like when you you have a hangover and you got a headache or you ⁓ had a head cold and you've got a in your and your head hurt. You know, it's a it's a very different experience than what a migraine or goes through. You know, their condition involves a a a complex neurological disorder that you know involves altered brain functions, sensory perceptions and pain pathways. You know, and the net net is you know, to describe what a migraine feels like to a non migraineure, ⁓ it's just extremely hard to explain. ⁓ our founder, Dr. Muta Jain, ⁓ does suffer with episodic migraines and he'll tell you that when they happen, i it you you you completely shut down your functionality. You you literally want to lop off your head. ⁓ and I am a non migraineur, ⁓ but I've talked to enough patients that ⁓ That have described very similar ⁓ experiences, if you will, and descriptors of of what a migraine feels like. And the net net is is unless you've had one, it's really hard to sympathize. ⁓ and I think that becomes a challenge, you know, for those of us that that don't suffer ⁓ with migraines. ⁓ these patients, you know, unfortunately, they become masters of hiding their pain. They they show up to work with. twenty percent battery power, right? They show up to family and friends events, ⁓ but they ⁓ deep down they feel horrible ⁓ if they can actually show up. ⁓ and you know, they're very resilient population, ⁓ but unfortunately that resilience ⁓ you know, becomes a little bit paradoxical in that it it oftentimes make it seem like their disease is less severe. ⁓ so there's a number of reasons there. I could I could go on as well about women's health. You know, two thirds of the population are women. And you know, unfortunately I don't think women's health garners the attention it needs. And ⁓ so anyways, ⁓ I could spend hours talking about it, but we're here to change the the narrative here and to help create a lot of awareness around, you know, the level of debilitation and ⁓ impairment that migraine can create. speaker-0: Yeah, no, absolutely. And I think that you've really done a great job encapsulating and describing perhaps the disconnect between the experience and and those who don't experience. One one observation is that clearly you have the ability to kind of read and assess people really well, which would suggest that you have a a strong level of empathy. And and I think that probably is part of the reason why being mission driven is so important to you in in the work that you do. But then also really the ability to understand what these patients are going through, even though you might not suffer from the condition itself. So the the work that that you all are doing with sheotronics is is tremendous and incredibly exciting. ⁓ and what we're talking about here is a neuromodulation implant. And to your earlier point, I would imagine for for these patients that are really suffering from migraine aura that a lot of them would be willing to do almost anything or try anything to to try to find relief. And they probably already cycled through motor multiple medications. What is it what does it mean to you to serve this patient population where medicine has had some clear limitations? speaker-1: Yeah. you know, to your point, ⁓ y the population that we are treating, ⁓ and the population we treated in our pivotal study have tried and and either failed or t have opted out of using, you know, existing pharmacologic options, right? They've tried the Botoxes, they've they've tried CGRPs, and yet they still have fifteen or more headache days per month. Which is really a stimulating if you think about it. ⁓ and so to your point, you know, many of these patients feel hopeless. You know, they are they are so symptomatic, they still carry a a very high degree of of ⁓ of of functional impairment. And they you know, at the same point in time as I talked about in my last answer, right, they're just an extremely resilient population. They keep powering through. They they've got optimism, right? They're they're they're they're constantly looking for new solutions. And that's really the, you know, the sort of ⁓ sweet spot for us, right? Is coming to the, you know, to the aid of of patients that ⁓ feel like they don't have a lot of other options right now, but yet they're still, you know, they're still encouraged, they're still optimistic that that hope is out there. ⁓ and so for us, it it is ⁓ you know, a a it's sort of a a ⁓ unbridled passion, you know, to get this therapy to market as fast as we can. ⁓ because we believe that neuromodulation has a chance to give hope to those that feel hopeless. And ⁓ and so ⁓ I'm encouraged. There's only so much I can share about our pivotal study. ⁓ just so you know, ⁓ we have ⁓ stopped enrollment of our pivotal and ⁓ we're prepared to unblind our data in the September ish time frame, let's call it Q three timeframe. And my hope is is that. ⁓ with that news, you know, comes ⁓ a a a new level of hope for patients that are in need that to your point maybe feel like they've been ⁓ you know, left behind, if you will, with the pharmac existing pharmacologic options. speaker-0: Right. Right. And and obviously we still have to go through all the the process and and see the clinical data and you've been running a very rigorous pivotal trial. But in your your pilot data, if you look at the 12 month ⁓ results from relief CM, you showed sustained symptom reduction in in these patients. Was there a point where you were looking at that data and you felt the shift from this might work to wow, I I really believe this is actually going to matter for these patients? speaker-1: Yeah, ⁓ I think to answer that question, I we have to look at the history of neuromodulation and ⁓ the treatment of head pain. ⁓ believe it or not, and this was something that I I learned along the way when I was was vetting this opportunity. the treatment of head pain, migraine, ⁓ and other phenotypes of head pain has been around for some time using neuromodulation. ⁓ it actually started a couple of decades ago, y you know, using externally, you know, external systems and ⁓ and then it that that evolved into actually using you know, non purpose built spinal cord stimulators to ⁓ tunnel so they would stick the can in the pectoral region or the lower back, and then they would tunnel up to the ⁓ at the time the occipital nerve. and you know, in that experience there was actually so there were so many positive indications that it was actually working. that it actually ⁓ you know caused the the likes of Boston Scientific, Medtronic and St. Jew to actually commission their own RCTs. Right. So back in the, I think it was 2010, 11, 12 timeframe, ⁓ they did execute their own RCTs, ⁓ again, using a non-purpose built system. and meanwhile, ⁓ you know, during that time all this off label use continued. It proliferated to the tune of I saw an estimate it was like seven hundred or fifty cases a year. ⁓ And so there were there were there were some indicators, right? There were yeah anecdotes that led, you know, to these investments in these RCTs. Unfortunate piece is is that they actually didn't meet their primary endpoint. ⁓ but all this experience led to a lot of our key learnings. ⁓ we believed at the time that they were using the wrong primary endpoints. The FDA was requiring more of a responder rate, like you see in many of the chronic pain studies like with spinal cord stem and whatnot. but but since that time with the advent of CGRP and Botox, the agency ⁓ has agreed that a better measure is is immune reduction and monthly headache day. That's our primary endpoint. ⁓ and actually that's an important stat because if you go look at their ⁓ those those original RCTs, if they had used that as a primary, a couple of them actually achieved statistical significance with that with that secondary endpoint. ⁓ but I I also mentioned probably an even bigger you know point in all this is ⁓ they had really high rates of mechanical failure. So meaning they the I I had mentioned to you that the leads were cro traversing the neckline, right? This region is where ⁓ you've obviously got ⁓ constant torquing and twisting of your head and whatnot, which was applying a lot of ⁓ you know, ⁓ force on the lead, which was leading to, you know, lead fracture, lead migration. ⁓ and again, that all traced back to the fact that they didn't have a purpose built system. Right. And then on top of it, the further evolution was that, you know, we believe that approaching, you know, not only the occipital nerve, but then targeting the superorbital nerve enhanced your ability to bring relief to to patients. So we folded all those key learnings into our approach. And ⁓ I'm very proud of the fact that ⁓ and I give our founders a lot of credit that the ⁓ you know, the hypothesis that a ⁓ subcutaneously placed, you know, head located system that took leads out of this this region ⁓ the neckline ⁓ would lead to lower rates of mechanical failure such as lead lead lead migration and that has played out. ⁓ in fact at one year in our ⁓ in our pilot study, again small sample size, but we had a zero percent rate of lead lead migration and fracture ⁓ at twelve months and and ⁓ again I can't share too much on our pi our pivotal, but I'm I'm hopeful that that same trend line, you know, carries out. speaker-0: Right, right. That's very exciting. And ⁓ you've done a fantastic job of kind of describing some of the early work which ha showed a signal, but there was also sounds like a lot of noise around the signal and what you've done with the purpose built technology is reduced the noise, focus signal only. And in addition with with kind of narrowing in on the clinical endpoints, it sounds like put you in a in a different category and position than some of the other attempts previously. I'm curious, ⁓ as you think about treating this patient population, ⁓ we've had a couple of conversations with leaders who have been tackling the field of epilepsy. And one of the points of conversation we've had is about turning down the noise ⁓ with with some of these patients, where maybe you don't go from, you know, fifteen occurrences of migraine R in a month down to zero, but you reduce it significantly. And in doing so, reduce the burden of disease. So this concept of r you know kind of reducing the noise or reducing the burden of disease is a a worthy achievement with some of these technologies. Is that sort of your your view that maybe you don't have to go all the way down to zero, but by dramatically reducing the burden that you really ⁓ transformatively change patients' outcomes and their are their outlooks? speaker-1: I I totally concur with with those sentiments and I think that is a a a a wise expectation, right? And I've been told by neurologists over and over to, you know, take a patient from nineteen headache days per month to zero, is possible. ⁓ and we actually saw a little bit of evidence of that in our in our pilot. ⁓ but to assume that you're gonna completely eradicate headaches for a population, you know, like this is not a realistic objective. ⁓ what they will tell you and what they've told me is ⁓ the focus needs to be on reducing ⁓ impairment and improving functionality. And that's multifactorial, meaning if you can ⁓ reduce a patient's headache days per month by a factor of say ⁓ three or five or six, ⁓ that's a big win in a in and of itself. ⁓ and if you look at the treatment effect size of the existing pharmaceuticals ⁓ in the pharmacologics, I mean a ⁓ CGRP treatment effect size is around two and a half days, but you know, it it but yet it's used with great frequency. So it shows you the level of of of you know sort of desperation and you know and and need there that a two and a half day treatment effect size is ⁓ is is is worthy of taking a a pretty expensive, you know, ⁓ annual course of therapy, if you will. however, you know, what what's not captured in that mean monthly headache day reduction ⁓ is the impact ⁓ that your therapy may have on, for instance, ⁓ the incidence of severe headaches. So that's an equally important measure. It's not caught in our primary endpoint. But ⁓ what I would suggest to you is if you can reduce mean monthly headache day by say four or five days. And you can have an effect on incidence of the the severe headaches, meaning when they happen, ⁓ even if they are moderate headaches, right? You you've taken them that that's the difference between a patient being in a dark room, sequestered, shutting down all stimuli, unable to go to the dinner table with their family, go to the grocery store, let alone go back to work. Those are the ones that knock you out, right? Those are the ones those are the headaches that that you know, again, you have full incapacitation. But if you're able to, you know, take those incidences of severe headaches and and actually convert them to moderate headache days or or, you know, no head or moderate headache days to no headache, now now you're you you know, the algorithm is starting to lead to improvements in functionality. ⁓ same would apply if you can have an effect on duration of headache, a focus on reducing you know, mean you know, monthly headache day, but then also having an effect on, you know, the incidence of those severe headaches. and that equal in and of itself equals a, you know, a restoration of functionality for patients. And that's really what we're trying to accomplish. So what I'm really excited about with with our our data when it comes out is not just looking at monthly headache day, but it's also looking at the effect that, you know, we're having on ⁓ severity of headaches, on on you know, the ⁓ duration of headaches, on on reductions in medication use, all those things that we're looking at in a secondary endpoint. ⁓ and the net net is the overarching goal is to reduce levels of impairment, to get patients out of dark rooms and then back to work, back to living life with their families, back to, you know, resuming hobbies, et cetera. ⁓ and that is again, like I said, kind of a multi factorial approach. speaker-0: Yeah, yeah, it's it's so critical. I mean, we want to be objective. We need to be objective in order to be able to evaluate these technologies and these therapies. But there's so many different vectors which you can align on to show improvement and overall, like you say, net net show improvement quality of life. So it's not just the number, but it's also the magnitude, it's the duration, ⁓ that also is critical for these patients. And if you can get them to have medication reduction on top of that, talk about a win win win win. So I'm curious. ⁓ you've you've now led companies through ⁓ FDA clearance, ⁓ IPOs, ⁓ major acquisition, and you came up through the commercial organization. How has that commercial foundation shaped the way that you think about building companies and and leading? speaker-1: I think at the end of the day, ⁓ you know, building ⁓ companies like this and and the you know, my my my previous companies, ⁓ you know, it it traces back to again gr grounding a team of incredibly accomplished individuals around a shared mission, ⁓ galvanizing them toward a shared goal. and ⁓ and then, you know, again, relentlessly executing, you know, on a a plant, whether it's commercial, I mean, and I'll I'll I'll give you a little bit of a flavor here. I mean, I joined here in the development phase. I did that with intention. ⁓ 'cause I'd never been through V and V, I'd never been through DBT, I'd never, you know, ⁓ been through execution of a pilot study. Everything else, everything in my career prior had been, you know, PMA. all the way through IPO, through private, you know, ⁓ company exit. ⁓ and I want to just round out the skill set. And and what I what I would say is that a lot of the fundamental characteristics still hold true. It's right. It's it's hiring unbelievably talented individuals that are mission driven and relentlessly focused on on on delivering on what we say we're gonna do. ⁓ you know, there are other elements ⁓ that I have learned along the way that revolve around, you know, things like, you know, making sure that you, you know, manage cash really tightly, right? Because I see a lot of startups ⁓ lean into big fundraises. When we when we raised, you know, our Series B, it was 66 million. And we could have gone and made a bunch of investments and whatnot, but it just but it just so happens that we have an incredible group of of individuals that were hired with intention here that I call Swiss Army knives. They're able to they you know, cover multiple domains. They have, you know, sophisticated skill sets that allows them to ⁓ pick up, you know, work streams, you know, even outside of their own domain. And ⁓ that has been a real, you know, key element of our ability to keep our burn down and ⁓ and you know and continue to build this company without sacrificing or shortchanging anything. So ⁓ you know, again, whether I came up through commercial or came up through R and D or came up through, you know, regulatory, I think at the end of the day, ⁓ you know, the the elements of building a commercial team are no different than building the elements of a, you know, ⁓ a early stage startup company. ⁓ and again, it focuses on hiring really good people that have diverse skill sets, that can wear multiple hats, that are just absolutely relentlessly focused on on doing what we say and saying what we do, you know. Did I say that right? Saying what we do do yes. You know what I'm saying. ⁓ and then also, you know, ⁓ are just grounded in a a shared mission and are are pulling and, you know, rowing the boat at the ti same time with the same amount of effort, you know, t to to ⁓ to deliver. So ⁓ hope that answers the question. speaker-0: Absolutely. At the at the end of the day, it's about putting the right people in the right role and giving them the right direction. And that's something that you've done exceedingly well throughout your entire career. And you can really see the hard work of the team paying off. You've had some recent announcements that are are really exciting. As you mentioned, you completed enrollment in your US Pivotal trial. Congratulations. Huge milestone. Took a lot of effort, but you you got through in in a really fast pace for these types of complex, challenging trials. And then you've also received dedicated procedure codes, which should set your technology up for for reimbursement here ⁓ in the US. So I have to ask, ⁓ what's next? speaker-1: Yeah. So I you know, I ⁓ I t the team will tell you I try not I to get too far out ahead of my skis. Like it is inflection point to inflection point. And we we have to your point crossed some really big ⁓ value inflecting milestones. ⁓ but the next one is, you know, September we're gonna you know, September, October we're gonna unblind our data. ⁓ I'm I'm excited about that. ⁓ you know, again, I I try not to get too excited until I actually see the results. I mean the results are the results and and ⁓ proofs in the pudding. ⁓ but that'll be our next milestone. Beyond that, ⁓ in queue you know, two of next year or thereabouts, we will ⁓ you know, achieve our safety milestone and then we will ⁓ file our final module ⁓ for PMA, ⁓ in support of PMA. And ⁓ and then from there we're looking at ⁓ you know, limited commercial launch in the twenty eight time frame. And ⁓ and we're off to the races so in in in terms of getting this therapy to patients in need. And ⁓ I'm really excited about that. I've had the been the benefactor of being able to be in front of patients, ⁓ both in our pilot and our pivotal. ⁓ and I will tell you that ⁓ I've heard stories ⁓ that w will will give you goosebumps ⁓ in terms of the ability of our ⁓ you know, our therapy, the promise of our therapy to potentially give, you know, patients their their lives back. and ⁓ we have work to do, but I will tell you that ⁓ and I'll give you a small anecdote that if ⁓ one of our patients up in New York is any indicator, you know, she had ⁓ she was a painter by trade. She has had put her paint brushes down for ⁓ you know, about a decade, ⁓ due to her ⁓ evolving migraines that were, you know, twenty plus days per month. And ⁓ after just a trial course of therapy, ⁓ she was able to paint a painting of her ⁓ you know, her hometown in in Rhode Island for one of our field clinical engineers. And I call that painting hope, ⁓ because it represents ⁓ the opportunity for us to again give patients ⁓ their lives back. gives them a an opportunity to resume their hobbies, to reunite with their families. And ⁓ at the end of the day, you know, we get one spin on this great globe of ours. And that's what I want to spend my time doing is is trying to, you know, have a meaningful impact on on patient lives. And and I think we're on the precipice of doing that. ⁓ again, a lot still has to be proved out, ⁓ but ⁓ to to be able to, you know potentially have that opportunity is something that I don't take lightly and I'm very grateful for. So ⁓ so that's kind of, you know, what's next. I mean beyond that, I I think that ⁓ you know, my hope is ⁓ that that we'll see the field of bioelectronic medicine really start to accelerate. I think we're starting to see more and more evidence that the these therapies work for chronic conditions, ⁓ that there may be in some cases ⁓ evidence of disease reversal. and ⁓ I will say that I believe that the ⁓ commitment to quality, robust clinical evidence ⁓ is there in the space. And I think we're starting to see, you know, ⁓ those trials, you know, prove out that, you know, I think we're we're we're just in the infancy of of ⁓ seeing what this this type of therapy can do for patients in multiple chronic conditions. speaker-0: Absolutely. And and that's incredibly powerful. So ⁓ unique ⁓ to you, you have a a brother Tyler who's also served as a med tech CEO. So I have to ask, what's Thanksgiving like in the mini household? Is it a support group, a competition? Or do refuse speaker-1: Yeah, so Ty Tyler and I Tyler and I both are ⁓ i obviously in the the the space. and you know, I I I wish I could tell you that we spend all of our time at Thanksgiving dinner talking about business, but usually it's it's ⁓ talking about a really nice bottle of wine, or maybe there's multiple bottles of wine, ⁓ in a good meal. So we don't we don't we don't spend a lot of time during Thanksgiving talking about things. ⁓ but that said, you know We have our careers have paralleled for a number of years. ⁓ well, for the bulk of our our careers and ⁓ and it's been really nice to have a built in ⁓ confidant, somebody you can on demand pick up the phone and ⁓ problem solve with, ⁓ you know, share a a tough day with, ⁓ share in successes ⁓ with and ⁓ you know, I like to think that ⁓ we've been great support systems for one another throughout and ⁓ you know, I mean I'm not gonna I mean I will I will point out that I've I have three exits and he's got two, so there's no complication at all. ⁓ and candidly, and I I'll say this to his face and you can ask him about this sometime, but you know, had his big brother Rob not talked him out of leaving J and J many years ago to go to NeoTrack, ⁓ he may still be a J and J. So, ⁓ but anyways, we and and all joking aside, we are ⁓ you know w feel very fortunate to to be able to ⁓ lead and build companies that we've been a part of and and ⁓ feel very fortunate to you know be a part of this this this ⁓ generation of innovation that's that's taken place in med tech. So ⁓ so yeah, anyways, I appreciate you asking that question. That was funny. speaker-0: Yeah, absolutely. So three three versus two, but I I believe you said earlier ⁓ that it's the number but also the magnitude. I think Tyler might mention. speaker-1: Yeah, for sure. Indeed. Indeed. So we'll see if I can't post some you know, something else. We'll see. speaker-0: So wrapping up here, any any advice for commercial leaders that are out there and maybe have been on a similar path as you who might be interested in leading a venture back med tech company one day? speaker-1: Yeah, you know, I I wish I had some life changing advice. I would just say ⁓ we all I think evolve at different rates. ⁓ if I if if you were to ask me back in two thousand eight, ⁓ ten, you know, would I ever see myself as a a CEO? ⁓ you know, I was a commercial leader at the time and and the answer probably would have been no. I I I had the good fortune of being invested in by the the people that I've talked to you about, right? You know, from Leslie to Lisa ⁓ to to to Fred. ⁓ and I've been surrounded by just unbelievable talent that has, you know, ⁓ allowed me to you know, sort of grow and and and evolve into the role that I'm in today and ⁓ the person that I am today. And ⁓ what I would just suggest is, you know, find you know, those ⁓ those mentors, right? And lean into them, learn from them, ⁓ extract every single, you know, possible ⁓ key learning that you can from ⁓ because if you get the right ones, they will ⁓ help you to help instill belief in yourself and help you to you know, refine your leadership capabilities and and attributes. And ⁓ and ultimately, you know, we'll be mentors for life. ⁓ I still talk to Lisa, you know, ⁓ Leslie, et cetera. And ⁓ you know, and I I give them a lot of credit for again taking a you know a a a ⁓ a very green sales leader ⁓ who didn't quite know exactly what they wanted to do and and made major investments in me, gave me seats at the table, ⁓ and ⁓ and that's you know, been a big reason why I've I think I've been able to, you know ⁓ be afforded the opportunities that I have and so anyways that that would be my my only advice is just find those mentors and lean into them and and learn everything you can from ⁓ speaker-0: Yeah, well that's that's fantastic advice. Well thank you thank you so much for joining, Rob. This was a a great, fantastic conversation. I think many, many will will benefit from speaker-1: Well thank you. It was great to see you again, Amari, and ⁓ appreciate the ⁓ the interest and opportunity to tell our story a little bit. speaker-0: Absolutely. And we'll be following the Sheratronic story very, very closely. We're we're really excited to see the pivotal data coming out later on in twenty twenty six. speaker-1: Keep your fingers crossed. Thanks so much. speaker-0: I will. And thank all of you for joining us today on Powering the Future Within. If this conversation inspired you, follow the show and share it with your med tech community. I'm Omari Bachnight. Stay inspired and keep innovating.